Weight Loss

Tirzepatide

Dual GIP/GLP-1 Agonist — Next-Generation Weight Management

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By targeting two incretin pathways simultaneously, it delivers superior weight loss results compared to single-agonist therapies.

Key Benefits

  • Superior weight loss vs single agonists
  • Dual hormone pathway activation
  • Improved glycemic control
  • Reduced cardiovascular risk factors
  • Better metabolic reset
  • Enhanced insulin sensitivity

Who It's For

  • Patients seeking maximum weight loss results
  • Those who haven't responded to other GLP-1 therapies
  • Adults with obesity and metabolic syndrome
  • Patients with type 2 diabetes

FAQs

How does Tirzepatide compare to Semaglutide?

Clinical trials show Tirzepatide produces greater weight loss — up to 22.5% of body weight — compared to semaglutide.

How often is it injected?

Once weekly subcutaneous injection, starting at a low dose and titrating up.